CRISPR THERAPEUTICS AG Cash and Cash Equivalents
CRISPR THERAPEUTICS AG (CRSP) had Cash and Cash Equivalents of $291.34 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-03
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $291.34M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $423.31M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $347.56M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $286.50M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $291.34M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $423.31M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $347.56M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $286.50M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $193.62M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $235.18M 10-Q · filed 2026-05-04 |
| 2024-12-31 | $298.26M 10-K · filed 2026-02-12 |
| 2024-09-30 | $225.67M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $484.47M 10-Q · filed 2025-08-04 |
| 2024-03-31 | $707.43M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $389.48M 10-K · filed 2026-02-12 |
| 2023-09-30 | $527.76M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $444.80M 10-Q · filed 2024-08-05 |
| 2023-03-31 | $344.41M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $211.88M 10-K · filed 2025-02-11 |
| 2022-09-30 | $494.15M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $496.89M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $683.91M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $923.03M 10-K · filed 2024-02-21 |
| 2021-09-30 | $1.01B 10-Q · filed 2022-11-01 |
| 2021-06-30 | $1.65B 10-Q · filed 2022-08-08 |
| 2021-03-31 | $1.13B 10-Q · filed 2022-05-09 |
| 2020-12-31 | $1.17B 10-K · filed 2023-02-21 |
| 2020-09-30 | $1.04B 10-Q · filed 2021-11-03 |
| 2020-06-30 | $945.07M 10-Q · filed 2021-07-29 |
| 2020-03-31 | $889.71M 10-Q · filed 2021-04-27 |
| 2019-12-31 | $943.77M 10-K · filed 2022-02-15 |
| 2019-09-30 | $629.72M 10-Q · filed 2020-10-28 |
| 2019-06-30 | $427.88M 10-Q · filed 2020-07-27 |
| 2019-03-31 | $437.55M 10-Q · filed 2020-04-28 |
| 2018-12-31 | $456.65M 10-K · filed 2021-02-16 |
| 2018-09-30 | $487.30M 10-Q · filed 2019-10-28 |
| 2018-06-30 | $319.74M 10-Q · filed 2019-07-29 |
| 2018-03-31 | $341.77M 10-Q · filed 2019-04-29 |
| 2017-12-31 | $239.76M 10-K · filed 2020-02-12 |
| 2017-09-30 | $253.52M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $272.26M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $288.87M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $315.52M 10-K · filed 2019-02-25 |
| 2016-09-30 | $228.61M 10-Q · filed 2017-11-08 |
| 2016-06-30 | $246.85M 10-Q · filed 2017-08-10 |
| 2016-03-31 | $200.60M 10-Q · filed 2017-05-11 |
| 2015-12-31 | $155.96M 10-K · filed 2018-03-08 |
| 2015-09-30 | $49.05M 10-Q · filed 2016-11-22 |
| 2014-12-31 | $945.00K 10-K · filed 2018-03-08 |
| 2013-12-31 | $361.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |